Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy

Oncogene

Volumn 34, Issue 9, 2015, Pages 1083-1093

  Kim, B ^a   Wang, S ^b   Lee, J M ^a   Jeong, Y ^a   Ahn, T ^a   Son, D S ^a   Park, H W ^a   Yoo, H S ^a   Song, Y J ^a   Lee, E ^a   Oh, Y M ^a   Lee, S B ^a   Choi, J ^a   Murray, J C ^b   Zhou, Y ^c   Song, P H ^a   Kim, K A ^a   Weiner, L M ^b  

^a Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^b GEORGETOWN UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; CRIZOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GROWTH FACTOR RECEPTOR; PROTEIN BCL XL; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; ITGB3 PROTEIN, HUMAN; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SAIT301;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CELL VIABILITY; DOSE RESPONSE; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TARGET CELL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PEPTIDE LIBRARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA3; MOLECULAR TARGETED THERAPY; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84938544763     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.51     Document Type: Article

References (52)

1. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012;107:325-333.
2. Garcia S, Dales JP, Charafe-Jauffret E, Carpentier-Meunier S, Andrac-Meyer L, Jacquemier J et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 2007;38:830-841.
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-925.
4. Wickramasinghe D, Kong-Beltran M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle (Georgetown, TX) 2005;4:683-685.
5. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Antiapoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci USA 2001;98:247-252.
6. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395.
7. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ et al. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene 2014;33:34-43.
8. Landi L, Minuti G, D'Incecco A, Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol 2013;25:130-136.
9. Scagliotti GV, Novello S, Von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39:793-801.
10. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Exp Opin Ther Targets 2012;16:553-572.
11. Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 2012;29:925-934.
12. Basilico C, Pennacchietti S, Vigna E, Chiriaco C, Arena S, Bardelli A et al. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. Clin Cancer Res 2013;19:2381-2392.
13. Sequist LV, Von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3315.
14. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Exp Opin Biol Ther 2011;11:1655-1662.
15. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810.
16. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946.
17. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006;103:2316-2321.
18. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714-726.
19. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A et al. N-methylated cyclic RGD peptides as highly active and selective alpha (V) beta (3) integrin antagonists. J Med Chem 1999;42:3033-3040.
20. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-3508.
21. Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A et al. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer 2010;9:121.
22. Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 2011;71:5255-5264.
23. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70:7580-7590.
24. Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S et al. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS One 2012;7:e39653.
25. Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M et al. Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. PLoS One 2013;8:e78398.
26. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York, NY) 2007;316:1039-1043.
27. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
28. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-9487.
29. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E et al. Autocrine activation of the MET receptor tyrosine kinasein acute myeloid leukemia. Nat Med 2012;18:1118-1122.
30. Singleton KR, Kim J, Hinz TK, Marek LA, Casas-Selves M, Hatheway C et al. A receptor tyrosine kinasenetwork composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factorreceptor drives growth and survival of head and neck squamous carcinoma cell lines. Mol Pharmacol 2013;83:882-893.
31. Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010;80:731-738.
32. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010;3: ra67.
33. Ju L, Zhou C. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell Int 2013;13:15.
34. Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC et al. beta1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res 2011;13:R84.
35. Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D et al. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res 2009;69:8620-8628.
36. Oh YM, Song YJ, Lee SB, Jeong Y, Kim B, Kim GW et al. A new anti-c-Met antibody selected by a mechanism-based dual-screening method: therapeutic potential in cancer. Mol Cells 2012;34:523-529.
37. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ et al. Reactivation of mitogenactivated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 2012;287:28087-28098.
38. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184 a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-121.
39. Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Slovak ML, et al. Fibroblast growth factorreceptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005;4:787-798.
40. Mohammadi M, Froum S, Hamby JM, Schroeder MC, Panek RL, Lu GH, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998;17:5896-5904.
41. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C et al. Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptorfamily of receptor tyrosine kinase. J Med Chem 2011;54:7066-7083.
42. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 2010;16:4217-4225.
43. Janne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 2009;8:709-723.
44. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010;9:1956-1967.
45. Iida M, Brand TM, Campbell DA, Starr MM, Luthar N, Traynor AM et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther 2013;14:481-491.
46. Langsenlehner U, Renner W, Yazdani-Biuki B, Eder T, Wascher TC, Paulweber B et al. Integrin alpha-2 and beta-3 gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 2006;97:67-72.
47. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factorreceptor (Met). J Cell Biochem 2000;78:465-475.
48. Burke PA, De Nardo SJ, Miers LA, Lamborn KR, Matzku S, De Nardo GL. Cilengitide targeting of alpha (v) beta (3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-4272.
49. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptorinhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70:6880-6890.
50. Corcoran RB, Cheng KA, Hata AN, Faber AC, Ebi H, Coffee EM et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23:121-128.
51. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-103.
52. Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, Sheppard KA et al. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov 2012;2:948-959.